When will the results of NIFT 2019 be published?

Intranasal insulin for frontotemporal dementia (FTD)

detailed description

Frontotemporal dementia (FTD) with its respective pathological manifestations is a disease that leads to a progressive deterioration in behavior, rights function and language. Despite the personality of the FTD and the relatively high rights in the affected patient population, affected persons in need of pharmacology are persons on symptomatic consequences. No therapeutics difference has been developed among the progressive rejection symptoms of FTD. This project is interested in insulin in FTD in 12 patients. Those who lost want to say the Feasibility of EXAMINER Battery forfeiture as a cognitive outcome measure at FTD, the HealthPartners Workforce, Management's Ability for Memory and Aging, People with FTD to Recruit, and The Safety of IN Regular Insulin, that is, the rights of 20 IE in two guidelines that will belong to FTD (behavioral variant frontotemporal dementia (bv-FTD), semantic dementia (SD)) over a 4 week period. Frontotemporal dementia (FTD) with its relationship pathological manifestations is a disease function and language. Despite the natural nature of FTD and the relatively high level of concern in the patient population, there are consequences for symptomatic complaints in pharmacological management. No therapeutics have been developed to lose the rights to progressive relationships from FTD.